Dr. Raphael Hofstein, President and Chief Executive Officer of Hadasit, HMO’s research and development arm, has announced the creation of a protocol which utilizes stem cell lines to generate dopaminergic neurons which when injected into the brain of Parkinson’s disease patients will replace damaged cells. This procedure is expected to reduce the disease’s debilitating symptoms. HMO is the second in the world to develop viable stem cell lines that are being used for cutting-edge research.

According to Robin Elliott, Executive Director of the Parkinson’s Disease Foundation, “In the long term, this protocol could represent a potentially magical approach to the treatment of Parkinson’s and other debilitating human diseases.”